# Waters<sup>™</sup>

Nota de aplicación

# Retention Time, Product Ion, and CCS Characterization of the Constituents of a FDA-Approved Small Molecule Pharmaceuticals Library

Michael McCullagh, Jeff Goshawk, Russell J. Mortishire-Smith

Waters Corporation



#### Abstract

A set of FDA-approved small molecule pharmaceuticals was used to produce a UPLC-IM-MS library, comprising retention time t<sub>r</sub>, precursor ion, product ions and CCS values for 1343 entries in ES+ mode and 950 entries in ES- mode. Ion mobility-enhanced mass spectrometry libraries incorporate additional cumulative specificity compared to conventional mass spectrometry libraries. They can be used to reduce false detection rates and increase the confidence of identification in complex matrices.

A non-targeted screening approach was performed in which CCS values were used alongside retention time, precursor, and product ions to evaluate a human urine sample. The xenobiotic exogenous components carbamazepine, carbamazepine-10, 11-epoxide, and acetaminophen were identified, as well as a variety of endogenous matrix components. When compared to the mass spectrometry library generated,  $\Delta$ CCS values <1% have been obtained routinely and identification was confirmed in conjunction with a product ion count  $\geq$ 1 and mass accuracy <5 ppm. The post processing workflow enabled false positive matches in the initial 60 detection results to be filtered to 5 identified compounds.

Verification of the extensive library generated has been performed using a non-targeted screen of a human urine complex biological matrix sample. The library generated can facilitate non-targeted screening to perform monitoring of therapeutic xenobiotics.

#### **Benefits**

- Ion mobility-enabled multifactor authentication mass spectrometry libraries afford additional specificity compared to conventional mass spectrometry libraries
- · Reduced false detections and increased confidence of identification in complex matrices
- The library t<sub>r</sub>, precursor ion and product ion information can be applied in assays that do not incorporate ion mobility data

### Introduction

High resolution mass spectrometers (HRMS) such as quadrupole time of flight mass analyzers (Q-TOF), have become more prevalent as screening tools in clinical, forensic toxicology and metabolite identification, where the constituents of interest are present in complex biological matrices such as urine and blood.<sup>1,2</sup> Using non-

targeted "full scan" data acquisition thousands of detections can be made in a single analysis, and can be followed by retrospective targeted data analysis. The drive for higher sample throughput is global, requirement for improved time efficiency and cost reduction has resulted in movement towards multiclass compound analysis. This approach has been used to analyse pesticides, mycotoxins, natural plant toxins<sup>3</sup> and organic contaminants,<sup>4,5</sup> which also reside within a variety of complex sample matrices, ranging from food<sup>6</sup> to environmental samples such as water effluent.<sup>7,8</sup> The purpose of a screening method is to rapidly detect and identify target compounds in the sample under investigation, with false detection rates being kept as low as possible. Using measured properties of a compound, such as the accurate mass, isotope pattern, and product ion spectrum, appropriate filters can be applied to determine the presence of a compound in a sample. However, for compounds of interest which are present only at low concentration, within complex biological matrices, using these properties alone to achieve matrix or analyte identification may prove to be more challenging and additional method development strategies need to be employed. For such complex analyses, the extra dimension of IM separation can help to mitigate such analytical challenges, as well as generate additional identification specificity via the collision cross section (CCS).

Using a previously reported mass spectrometry library generation strategy,<sup>9</sup> a set of commercially available FDA approved drugs was characterized using UltraPerformance Liquid Chromatography-Ion Mobility Mass Spectrometry (UPLC-IM-MS). The strategy employed enables retention time (t<sub>r</sub>), precursor ions, product ions and CCS to be determined. The commercialization of IM instrumentation (Waters Corp: SYNAPT (2006), Vion (2015), Cyclic IMS (2018)), has led to an increase in peer reviewed papers (>1250 by 2014/2015)<sup>10-11</sup> and analytical strategies utilizing CCS as an additional endpoint to aid identification specificity have been developed, for example pesticide screening assays.<sup>12</sup> The routine use of CCS for small molecule analysis has since increased across multiple areas of research including pharma (metabolism, metabolomics, lipids) and food safety (veterinary drugs, mycotoxins, steroids, natural product screening, natural toxins). CCS-searchable libraries have been generated whereby use of a CCS metric can be used to increase cumulative specificity of identification as well decrease false detections. Generation of natural product and food additives libraries has recently been presented, as well as an evaluation of the long-term robustness and reproducibility of CCS measurements.<sup>14-17</sup>

UPLC-IM comprises ion mobility (gas phase separation prior to MS analysis) coupled with UPLC (neutral species separation).<sup>18,19</sup> The timescale of UPLC (seconds), IMS (milliseconds), and time-of-flight MS (microseconds) are compatible with the requirement of high throughput analysis of complex samples. Ion mobility separation of compounds result from gas phase ions being separated within a gas-filled travelling wave ion mobility (TWIM) RF ion guide of the mass spectrometer, prior to the mass analyzer. Mobility separation is obtained by driving packets of ions through an inert buffer gas (nitrogen) or using a relatively weak electric field. The number of collisions between ions and the buffer gas cause drift time differences. The

resultant separation is based on the application of repeating DC pulses along the RF ion guide; periodically ions are overtaken by the pulses or waves, where less mobile species are overtaken more frequently than higher mobility species, hence the time to traverse the device is mobility dependent and is a function of factors such as the ion mass, charge and shape. Ion mobility provides a third dimension of separation to that of LC (hydrophobicity) and MS (m/z).

We have generated an extensive library of FDA approved drug small molecules and used it to perform a nontargeted urinary screen of a patient sample to identify administered pharmaceutical compounds.

## Experimental

#### Sample Description

Human urine sample diluted 10:1 ( $H_2O$ ).

Sample taken 6 hrs after medication was administered.

Carbamazepine Dosage: 2 x 200 mg tablets.

Acetaminophen Dosage: 2 x 500 mg tablets.

#### LC Conditions

LC system:	ACQUITY UPLC I-Class
Vials:	LCMS Certified Clear Glass 12 x 32 mm Screw Neck Total Recovery Vial, with Cap and Pre-slit PTFE/Silicone Septa, 1 mL Volume, [600000671CV]
Column:	ACQUITY UPLC HSS T3 C <sub>18</sub> (100 mm x 2.1 mm, 1.8 μm) Column
Column temp.:	40 °C

Sample temp.:	4 °C
Injection volume:	10 µL
Flow rate:	0.5 mL/min
Mobile phase A:	Water (containing 0.1% formic acid v/v)
Mobile phase B:	Acetonitrile (containing 0.1% formic acid v/v)

### Gradient Table

Time (min)	Flow (mL/min)	%A	%B	Curve
0	0.5 mL/min	99.0	1	initial
1	0.5 mL/min	99.0	1	6
3	0.5 mL/min	85	15	6
6	0.5 mL/min	50	50	6
9	0.5 mL/min	5	95	6
10	0.5 mL/min	5	95	6
10.1	0.5 mL/min	99	1	6
12	0.5 mL/min	99	1	6

#### **MS** Conditions

MS system:

SYNAPT G2-Si

Ionization mode:

ESI+

Acquisition range:	<i>m/z</i> 50–1200
Acquisition rate:	10 spectra per second
Capillary voltage:	1.5kV
Desolvation temp.:	550 °C
Source temp.:	150 °C
Lockmass:	Leucine enkephalin ( <i>m/z</i> 556.2766)
Acquisition mode:	HDMS <sup>E</sup>
Collision energy:	Collision energy ramp (15 to 25 eV)
IMS parameters:	Defaults include: T-Wave Velocity Ramp = Start: 1000 m/s End: 300m/s, T-Wave Pulse Height = 40V and a gas flow of helium 180 mL and nitrogen 90 mL (buffer gas) for the respective gas cells was used, giving an IM cell pressure of ~3.2 mBar
Calibration:	IMS/ToF Calibration Kit (186008113) (Waters Corp. UK)
Data Management	
Chromatography software:	MassLynx v4.2 SCN 983
MS software:	MassLynx v4.2 SCN 983
Informatics:	UNIFI v1.94 Library average CCS values were determined

# Results and Discussion

The small molecules library generated comprises 1453 compounds. For positive electrospray mode there are 1343 entries are included (comprised of 1277 [M+H]<sup>+</sup> and 958 [M+Na]<sup>+</sup> species). In negative ion mode the library contains 950 entries (comprised of 903 [M-H]<sup>-</sup> and 238 [M-H+HCOO]<sup>-</sup> species. (FDA Approved Drugs Profiling CCS Library <a href="https://ims.waters.com/discover-ims-ms/ccs-libraries/">https://ims.waters.com/discover-ims-ms/ccs-libraries/</a>> ).

The rationale for the generation of a UPLC-IM-MS library is two-fold. Primarily the library facilitates a high degree of specificity to detect the presence or absence of therapeutic xenobiotics. The library specificity also provides a route to distinguishing components of interest from the exogenous/endogenous components of complex biological matrices such as urine. The complexity of human urine matrix is illustrated in Figure 1, where the extracted base peak ion chromatogram is comprised of 1000's of major and minor intensity components (8646 candidate masses detected (> 100 counts intensity)). The corresponding ion mobility separation, illustrating the combined peak capacity of UPLC-IM, is also shown where chromatographically coeluting components are separated in the IM dimension. This facilitates generation of non-targeted single component precursor ions with corresponding product ion spectra, from the drift time and retention time aligned species. This is illustrated for the identification of carbamazepine in Figure 2.




Figure 1. UPLC-IM-MS separation obtained for non-targeted urinary screening.

	ns and	Components • •	8		MMCC FDA PLA	TES	Carbama	zepine						A	Filters
In	ection	5 ° ° 🖻	6	omponent Summary *										<b>*</b> * * (1	
			4	Component name	Identification status	Observed m/z	Mass error (ppm)	Expected RT ( 1 + Ob	served RT (min)	Retention Time Error (min)	Observed CCS (Å <sup>2</sup> )	Expected CCS (Å <sup>2</sup> )	CCS delta (%)	Expected Fragments Found	dd
100		and the second	44	Tetracaine	Identified	265.1922	4.4	5.40	5.37	-0.03	162.4	171.5	-5.31	0	+H
	atus			Oxcarbazepine	Identified	253.0964	-2.8	5.45	5.47	0.02	151.3	152.0	-0.46	1	+H
		Gentibrozi		Aniracetam	Identified	220.0969			5.49		145.3	141.4			+H
		Furazolidone	47	Prednisolone	Identified	361,1994			5.62		185.4	183.1			
		Fescterodine	40	Prednisone	Identified	359.1843	-2.6		5.65		182.9	182.1	0.46		
		Fasudi			Identified	363.2161	-1.3		5.58		186.5	186.0			
		Estiol		i i jai o control i contro	Identified	328.1198			5.64		176.0	175.1	0.54		
		Doripenem		an open of the second s											
		Dorlpenem		Carbamazepine	Identified	237.1032			5.90	271701	148.9	148.2			
		DL-Camitine		Fesoterodine	Identified	412.2833			5.97	-0.05	198.7	199.5			
		Dextrose	53	Dexamethasone (DHAP)	Identified	415.1906	3.6	6.04	6.12	0.08	193.7	214.9	-9.88	0	+Na
		Dexamethasone (DHAP)	1												
		Demeclocycline HCI	100	iromatograms •				13 % 5 in % .	ate (	Sorema					
		DEET	le	rematograms v						operio					1000
		Cytarabine								1.5e6-1				237.1032-	
		Cyclophosphamide		1.25e5 t		Cart	pamazepine			2				257.1052	
		Cyclandelate		1.2000			5.90			5 1e6					
	0	Cinicipine								00100					
		Carbamazepine		100000-						Intensity [Counts] 262					
		Eisoprolol				E L				Se5-					
				. 1									194.09	64 229.1256	
	Ø	Derzethonium	ts							0					
		Berzethonium Azacitidine	ounts	75000							20 140	160			10
	0		y [Counts	75000					)	1	20 140	160	180 2	220 2	40
	0	Azacitidine	nsity [Counts	75000						1	20 140	160			
	000	Azacitidine Artemether	ntensity [Counts	75000 50000						1	20 140	160	180 2		
	0000	Azacilidine Artemether Aniracetam	Intensity [Counts]	5000-						1	20 140	160	194.09		
	00000	Azacilidine Artemether Arinsolam Aminophyline (sub-structure)	Intensity [Counts	75000 50000- 25000-						1	20 140		194.09		
	000000000000000000000000000000000000000	Azacildine Artemether Arimoetaum Arimoetaum Animoetaum Animoetaum Animoetaum Mizapride	Intensity [Counts]			N				1	20 140		194.09 ** 192.0806	65 237.1030-	
	0 0 0 0 0 0	Azacilidine Artenetiker Artenetiker Aninophylline (sub-structure) Michael (Acadesine)	Intensity [Counts]			N				ounts]	20 140		194.09 ** 192.0806		
	0 0 0 0 0 0 0 0 0 0 0	Azəclidine Artenetler Artenetler Animophyline (ub-dructure) Animophyline (ub-dructure) Animophyline (ub-dructure) Alanopine Adenopine Adenopine	Intensity [Counts]		3 4	5 6	7 8	9 10	11 12	Intensity (Counts)	20 140		194.09 192.0806	65 237.1030- 95.0993	40
	0 0 0 0 0 0 0 0 0	Azolidine Artender Minacetam Minacetam Minaghile (ub-discture) Alzagride Alcolaries) Admobile Acetanilde	Intensity [Counts]	25000-			- <u>1</u> 1			Intensity (Counts)			194.09 192.0806	65 237.1030 95.0993	-

Figure 2. Post-acquisition processing workflow filtered detection results (identified count 60) for screening using FDA approved drug small molecule library, applied tolerance  $t_r$  0.1 min, and mass accuracy +/-5pm.

Including carbamazepine, using typical non-targeted screening tolerances of 5ppm and a retention time

tolerance 0.1 min, 60 identifications were made. Applying a 2%  $\Delta$ CCS tolerance, 23 false detections were removed (see Figure 3). Application of an identification criterion of at least one expected product ion (listed in the UPLC-IM-MS library) further removes 18 false positives, resulting in 5 final detections (see Figure 4).

Injections:	6 X - P		MMCC FD/									
		omponent Summary *										
Components (MMC	TEACEARD AND AND A	Component name						Retention Time Error (min)				
d Status Name	1-10	Carbamazepine	Identified	237.1032		5.91	5.90	-0.01	148.94	0.075100		2 +1
Ø Mepiroxo		Lowapine	Identified	328.1198	-4.0	5.65	5.64	-0.01	176.04			0 +1
O Loxapine	11	riyurocorusone	Identified	363.2161	-1.3	5.61	5.58	-0.03	186.51			1 +1
Ø L-carnitin	e 12	Freurisone	Identified	359.1843	-2.6	5.56	5.65	0.09	182.90		0.46	0 +1
Ansopra	zole 13	riedinatione	Identified	361.1994	-4.3	5.55	5.62	0.07	185.42		1.28	0 +1
Ø i-Inositol	14	Oxcarbazepine	Identified	253.0964	-2.8	5.45	5.47	0.02	151.32	152.01	0.46	1 +1
Hydrocor	tisone 15	Cyclophosphamide	Identified	283.0152	4.2	5.15	5.17	0.02	152.24	152.88	-0.42	0 +1
@ Gemfibro		Benzethonium	Identified	435.3122	3.3	4.71	4.74	0.03	194.38	194.48	-0.05	0 +1
Ø Furazolid		Furazolidone	Identified	226.0459	0.4	4.52	4.43	-0.09	141.92	144.66	-1.90	0 +
@ Fesoteror	10	Acetanilide	Identified	136.0760	2.6	4.45	4.55	0.10	124.09	124.34	-0.20	0 +
Ø Estriol		1										
Ø Doripene	m	tobilly Traces				7	- 🕂 🖂 🚺	cettra •			CIT.	
Ø Doripene								and the second se				
Ø DL-Carnit		2.5e5	Carbama	zepine				1.5e6-				237.1032-
								2				
O Dextrose												
Dextrose     Demeclo	orline HCI						- and	1e6-				
Ø Demeclo	cycline HCI	2e5-					to an and	1e6-				
Demeclo     DEET							andina (Conserva-	1e6- 5e5-				
<ul> <li>Demeclo</li> <li>DEET</li> <li>Cytarabir</li> </ul>							tatana (Canada)	1e6- 5e5-		10	4 00 64 2	
Demeclo     DEET     Cytarabin     Cyclopho							latonchi (f.	0			4.0304	29.1256
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande	e sphamide	1.5e5-					and Intraction (Canada		140 10	194 50 180	4.0964 2.	
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande     Cilnidipin	e sphamide	1.5e5-					8	0-120	140 16	50 180	200	29.1256
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande     Cilnidipin     Carbama	e sphamide late e tepine e tepine						8	0-120	140 16	50 180 194	200	29.1256
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande     Cilinidipin     Carbama     Benzetho	e sphamide set set set set set set set set set se	1.5e5-					8	0-120	140 16	50 180 194	200	29.1256
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande     Cilnidipin     Carbama     Benzetho     Artemeth	e sphamide state s	1.5e5-					8	0-120	140 16	50 180 194	200	29.1256
Demeclor     DEET     Cytarabir     Cyclopho     Cyclande     Cilnidipin     Carbama     Benzetho     Artemeth     Aminoph	e sphamide date 27799999999999999999999999999999999999	1.5e5-					8	0-120	140 11	50 180 194 192.080	200	29.1256
Demeclo     DEET     Cytarabin     Cyclopha     Cyclande     Cyclande     Culnidjeni     Carbama     Benzetha     Aminoph     AICAR (A	e sphamide s	1.5e5-					1860 - 16 Annalds -	0	140 11	50 180 194	200	29.1256 220 240 237.1030-
Demeclo     DEET     Cytarabir     Cyclopho     Cyclande     Cilnidipin     Carbama     Benzetho     Artemeth     Aminoph	e sphamide stee 23 are sphamide stee 24 are	1.5e5-	2 3 4	4 5	6 7	8 9	8	0-120		50 180 194 192.080	200	29.1256 220 240 237.1030- 220.0753

Figure 3. Post-acquisition processing workflow filtered detection results (identified count 37) for screening against FDA approved drug small molecule library, applied tolerance  $t_r$  0.1 min, and mass accuracy +/-5pm and  $\Delta$  CCS <2%.





Figure 4. Post-acquisition processing workflow filtered detection results (identified count 5) for screening against FDA approved drug small molecule library, applied tolerance  $t_r$  0.1 min, and mass accuracy +/-5pm,  $\Delta$  CCS <2% and ≥1 product ion.

The largest response was observed for carbamazepine, which was identified based on the tolerance criteria for accurate mass measurement of 5 ppm (3.9 ppm),  $t_r$  tolerance of 0.1 min (0.01 min), product ion count  $\geq 1$ (2) and  $\Delta$ CCS <2% (0.51%). This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain. Carbamazepine is a globally prescribed medication, with 6 million prescriptions (2011) and 3.5 million (2017) in USA alone. Carbamazepine is used to prevent and control seizures. Figure 4 also shows the identification of endogenous compounds DL-carnitine (derived from an amino acid, is found in nearly all cells of the body) and hydrocortisone (a natural substance (corticosteroid hormone) made by the adrenal gland). Oxcarbazepine, was also identified, however, it is believed that the correct identification is the alternative assignment, the carbamazepine-10, 11-epoxide metabolite (CCS 151.8 Å <sup>2</sup>). Exogenous theophylline was also identified with an accurate mass measurement within 3.2 ppm, retention time within 0.01 min, product ions (2) and  $\Delta$ CCS (<0.37%). While Theophylline is used to prevent and treat respiratory disorders, a likely reason for its detection is that the urine was obtained from a subject that had consumed coffee. Caffeine belongs to a group of compounds known as the xanthines and is metabolised to theophylline. To further support the hypothesis of the source of theophylline in the urine sample, further interrogation of the data was performed. The precursor, product ion, and CCS values of caffeine from a natural products library were entered into the analysis method. The identification of caffeine was confirmed (see Figure 5) with accurate mass measurement (-1.0 ppm), product ions (4) and  $\Delta$ CCS (0.06%). Nontargeted screen strategies typically aim for a false detection rate of <5%. The sequential application of combined filtering parameters to reduce false detections in a post processing workflow are presented in

#### Table 1.



*Figure 5. Additional analytes identified utilizing natural products and forensic toxicology libraries.* 

Post processing workflow	Mass accuracy tolerance	ΔCCS	Expected	Number of detections	False detections removed
step			fragments		
1	5ppm			60	
2	5ppm	<2%		37	23
3	5ppm	<2%	>1	5	55

Table 1. Sequential application of combined workflow filtering parameters to reduce false detections.

During manual data review, evidence indicating the subject was also taking acetaminophen was observed, therefore the corresponding CCS and precursor ion data (from a forensic toxicology library) was also entered into the analysis method. Retention time independent identification of acetaminophen was also confirmed using accurate mass measurement (0.3 ppm), product ion (1) and  $\Delta$  CCS (0.57%). Enhanced specificity, combined with analysis flexibility is illustrated, where both acetaminophen and caffeine, were identified based on precursor ion, product ion and CCS alone, in conjunction with a wide retention time tolerance. Retention time information was not available, because the libraries from which the CCS and product ion information were obtained for these compounds used different chromatographic conditions, to those described herein. Further confidence in detection of acetaminophen could be gained from additional identification of metabolites, acetaminophen glucuronide ( $t_r$  2.48 min, observed CCS 181 Å<sup>2</sup>) and acetaminophen sulphate ( $t_r$  2.82 min, observed CCS 149.7 Å<sup>2</sup>). The approach illustrates the versatility of the UPLC-IM libraries being generated and the utility of additional analytical selectivity of CCS values.

### Conclusion

A UPLC-IM-MS library of small molecules FDA-approved pharmaceuticals (1343 ES+ and 950 ES-) was generated comprising retention time t<sub>r</sub>, precursor ion, product ions, and CCS values. This library can be used to facilitate non-targeted screening to perform drug monitoring and illicit drug use. Verification of the library generated has been performed using a non-targeted screen of a human urine complex biological matrix sample. The research performed has produced only one detection requiring further investigation, where oxcarbazepine was observed, which could be rationalized and reassigned. Exogenous xenobiotics and natural endogenous species have been identified; no false detections were observed. For the research performed UNIFI functionality enabled rapid reassignment of a suspected false detection. The versatility of UPLC-IM libraries has been illustrated, using the FDA approved pharmaceutical drugs library, natural products and forensic toxicology library entries. Utilizing CCS in a UNIFI post-acquisition processing workflow to filter detection results for non-targeted screening assays provides unparalleled targeted data review flexibility, in a non-targeted analytical environment.

### References

- Sundström M, Pelander A, Ojanperä I. Comparison Between Drug Screening by Immunoassay and Ultra-High Performance Liquid Chromatography/High-Resolution Time-Of-Flight Mass Spectrometry in Post-Mortem Urine. *Drug Test. Anal.* 2015;7:420–427.
- Mollerup CB, Dalsgaard PW, Mardal M, Linnet K. Targeted and Non-Targeted Drug Screening in Whole Blood by UHPLC-TOF-MS with Data-Independent Acquisition. *Drug Test. Anal.* 2016;DOI: 10.1002/dta.2120.

- Dzumana Z, Zachariasovaa M, Veprikovaa Z, Godulab M, Hajslovaa J. Multi-Analyte High Performance Liquid Chromatography Coupled to High Resolution Tandem Mass Spectrometry Method for Control of Pesticide Residues, Mycotoxins, and Pyrrolizidine Alkaloids. *Anal. Chim. Acta*. 2015;863:29–40.
- Pérez-Ortega P, Lara-Ortega FJ, García-Reyes JF, Gilbert-López B, Trojanowicz M, Molina-Díaz, A. A Feasibility Study of UHPLC-HRMS Accurate-Mass Screening Methods for Multiclass Testing of Organic Contaminants in Food, *Talanta* 160 (2016) 704–712.
- Pérez-Ortega P, Lara-Ortega FJ, Gilbert-López B, Moreno-González D, García-Reyes JF, Molina-Día A. Screening of Over 600 Pesticides, Veterinary Drugs, Food-Packaging Contaminants, Mycotoxins, and Other Chemicals in Food by Ultra-High Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (UHPLC-QTOFMS). *Food Anal. Methods*. 2017;10:1216–1244.
- 6. Romero-González R. Food Safety: How Analytical Chemists Ensure It. Anal. Methods. 2015;7:7193–7201.
- Coscollà C, León N, Pastor A, Yusà V. Combined Target and Post-Run Target Strategy for a Comprehensive Analysis of Pesticides in Ambient Air Using Liquid Chromatography-Orbitrap High Resolution Mass Spectrometry. J. Chromatogr. A. 2014;1368:132–142.
- Sjerps RMA, Vughs D, van Leerdam JA, ter Laak TL, van Wezel AP. Data-driven Prioritization of Chemicals for Various Water Types Using Suspect Screening LC-HRMS. *Water Research*. 2016;93:254–264.
- 9. Goshawk J, Barknowitz G, McCullagh M. A Workflow for Automatic MS Library Creation from Time-of-Flight Full-Spectra Data Processed in UNIFI. 720006783EN < https://www.waters.com/webassets/cms/library/docs/720006783en.pdf> . 2020 Feb.
- Giles K, Pringle SD, Worthington KR, Little D, Wildgoose J, Bateman RH. Applications of a Travelling Wave-Based Radio-Frequency Only Stacked Ring Ion Guide. *Rapid Commun Mass Spectrom*. 2004;18:2401–2414.
- Pringle SD, Giles K, Wildgoose J. An Investigation of the Mobility Separation of some Peptide and Protein Ions Using a New Hybrid Quadrupole/Travelling Wave IMS/oa-ToF Instrument. *Int J Mass Spectrom*. 2007;261(1):1–12.
- 12. Goscinny S and McCullagh M. A Novel Approach to the Reduction of False Positive and Negative Identifications in Screening of Pesticide Residues in Food Analysis. Proceedings of the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Minneapolis, Minnesota. June, 2013.
- 13. S. Goscinny, McCullagh M, Far J, De Pauw E, Eppe G. Towards the Use of Ion Mobility Mass Spectrometry

Derived Collision Cross Section as a Screening Approach for Unambiguous Identification of Targeted Pesticides in Food. *Rapid Commun Mass Spectrom.* 2019;33(S2):34–48.

- 14. McCullagh M, Goshawk J, Goscinny S. Use of Ion Mobility TWCCSN2 Values in Non-Targeted Food Additives Screening. Waters Application Note 720006768EN < https://www.waters.com/webassets/cms/library/docs/720006768en.pdf> . 2020 Feb.
- McCullagh M, Goshawk J, Mortishire-Smith R. Enhancing Analysis Specificity and Deconvolution of Natural Products Using a Positive Mode Ion Mobility Mass Spectrometry Library. Waters Application Note 720006650EN <a href="https://www.waters.com/webassets/cms/library/docs/720006650en.pdf">https://www.waters.com/webassets/cms/library/docs/720006650en.pdf</a>> . 2019 Sep.
- McCullagh M, Mortishire-Smith R, Goshawk J. UnParalleled Multi-Factor Authentication Mass Spectrometry of Complex Natural Products Utilizing UPLC and Ion Mobility. Waters Application Note 720006791EN <a href="https://www.waters.com/webassets/cms/library/docs/720006791en.pdf">https://www.waters.com/webassets/cms/library/docs/720006791en.pdf</a>> . 2020 Mar.
- McCullagh M, Wood M, Mistry N, Goscinny S, Dalsgaard P. Small Molecule Ion Mobility Investigations into Cross-Platform and Long-Term Robustness of a CCS Metric. Waters Application Note 720006769EN <a href="https://www.waters.com/webassets/cms/library/docs/720006769en.pdf">https://www.waters.com/webassets/cms/library/docs/720006769en.pdf</a>> . 2020 Mar.
- Giles K, Pringle SD, Worthington KR, Little D, Wildgoose J, Bateman, RH. Applications of a Travelling Wave-Based Radio-Frequency Only Stacked Ring Ion Guide. *Rapid Commun. Mass Spectrom*. 2004, 18, 2401.
- Pringle SD, Giles K, Wildgoose J. An Investigation of the Mobility Separation of Some Peptide and Protein Ions Using a New Hybrid Quadrupole/Travelling Wave IMS/oa-ToF Instrument. *International Journal of Mass Spectrometry.* 2014, 26, 1–12.

## Featured Products

SYNAPT G2-Si High Definition Mass Spectrometry <a href="https://www.waters.com/134740622">https://www.waters.com/134613317</a> ACQUITY UPLC I-Class PLUS System <a href="https://www.waters.com/134613317">https://www.waters.com/134613317</a> MassLynx MS Software <a href="https://www.waters.com/513662">https://www.waters.com/134613317</a> UNIFI Scientific Information System <a href="https://www.waters.com/134801648">https://www.waters.com/134613317</a>

720007175, March 2021

© 2021 Waters Corporation. All Rights Reserved.